Patent ID: 11912780
Assignee: ACTINIUM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 7:
8. A method for treating a human subject afflicted with a non-cancerous disorder treatable via genetically edited hematopoietic stem cell therapy, the method consisting essentially of:
(i) administering to the subject an effective amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, wherein the radiolabeled anti-CD45 antibody is radiolabeled BC8, wherein depleting the subject's hematopoietic stem cells consists of reducing a population of hematopoietic stem cells in the subject by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%, and
(ii) after a suitable time period, performing the genetically edited hematopoietic stem cell therapy on the subject to treat the non-cancerous disorder,
wherein the genetically edited hematopoietic stem cell therapy is allogeneic or autologous stem cell therapy,
wherein the non-cancerous disorder is selected from the group consisting of a hemoglobinopathy, a congenital immunodeficiency, and a viral infection, and wherein
(i) the radiolabeled BC8 is 131I-BC8, and the effective amount of 131I-BC8 is from 10 mCi to 1,200 mCi, or
(ii) the radiolabeled BC8 is 225Ac-BC8, and the effective amount of 225Ac-BC8 is selected from the group consisting of from 0.1 μCi/kg to 5.0 μCi/kg subject weight, from 0.1 μCi/kg to 1.0 μCi/kg subject weight, from 1.0 μCi/kg to 3.0 μCi/kg subject weight, and from 3.0 μCi/kg to 5.0 μCi/kg subject weight.